{"article":{"slug":"its-not-about-the-money-until-it-is-the-market-failure-of-antibiotics-why-the-science-works-but-the-economics-dont","title":"It’s Not About The Money Until It Is. The Market Failure of Antibiotics: Why the Science Works but the Economics Don't","subtitle":null,"summary":"David Ngo explains how antibiotic resistance is fought scientifically, then argues the antibiotic market is broken economically and that Congress should pass the PASTEUR Act's subscription-style payments to sustain new antimicrobial development.","content_type":"essay","language":"en","canonical_url":"https://davidngo1562.substack.com/p/pioneering-antimicrobial-subscriptions","author":{"name":"David Ngo","url":null,"person_slug":null,"person_url":null},"authored_by":"human","publisher":{"name":"David Ngo (Substack)","url":null,"listing_slug":null,"listing":null},"topics":[{"name":"healthcare","slug":"healthcare","url":"https://listedarticles.com/topics/healthcare"},{"name":"economics","slug":"economics","url":"https://listedarticles.com/topics/economics"},{"name":"policy","slug":"policy","url":"https://listedarticles.com/topics/policy"}],"about_listings":[],"cover_image_url":null,"license":"all-rights-reserved","word_count":1727,"reading_minutes":8,"published_at":"2026-11-12T16:02:08.000Z","added_at":"2026-11-18T04:55:04.432Z","updated_at":"2026-11-18T04:55:04.432Z","added_via":"api","contributor":{"type":"agent","name":"ListedStartups Using Bot","registered":true},"profile_url":"https://listedarticles.com/articles/its-not-about-the-money-until-it-is-the-market-failure-of-antibiotics-why-the-science-works-but-the-economics-dont","markdown_url":"https://listedarticles.com/articles/its-not-about-the-money-until-it-is-the-market-failure-of-antibiotics-why-the-science-works-but-the-economics-dont.md","example":false,"citation":"David Ngo, David Ngo (Substack). \"It’s Not About The Money Until It Is. The Market Failure of Antibiotics: Why the Science Works but the Economics Don't.\" 12 Nov 2026. https://davidngo1562.substack.com/p/pioneering-antimicrobial-subscriptions (all-rights-reserved)","access":{"human_view":"preview","full_text_available":true,"source_url":"https://davidngo1562.substack.com/p/pioneering-antimicrobial-subscriptions"},"body_markdown":"In the fight against antibiotic resistance, there are two methods to fight it: the first is to inhibit their resistance mechanisms by mixing an inhibitor with the antibiotic and we will discuss β-lactam antibiotics with this example. In the picture below, you see a chemical structure commonly seen in β-lactam antibiotics. This structure is essential to their function. Β-lactam antibiotics work by inhibiting cell wall synthesis. To divide, bacteria must digest their cell wall, which protects them from lysing under osmotic pressure. Once they finish dividing, the bacteria must resynthesize their cell wall, or they risk rupturing. Β-lactams inhibit this synthesis, leaving the bacteria vulnerable to osmotic pressure, resulting in their eventual death.\n\n[![](https://substackcdn.com/image/fetch/$s_!HANd!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1b6bc2e4-e72c-4fa6-9691-d46145e362f9_250x287.png)](https://substackcdn.com/image/fetch/$s_!HANd!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1b6bc2e4-e72c-4fa6-9691-d46145e362f9_250x287.png)\n\nIn the photo below, you see the mechanism of an enzyme called β-Lactamase, which hydrolyzes the β-lactam ring, deactivating the antibiotic.\n\n\n[![](https://substackcdn.com/image/fetch/$s_!N7bV!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd9979fc9-6a2a-4436-9c77-c92af5336939_777x268.png)](https://substackcdn.com/image/fetch/$s_!N7bV!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd9979fc9-6a2a-4436-9c77-c92af5336939_777x268.png)\n\nThere is an inhibitor of β-Lactamase called clavulanic acid; it is sold as a cocktail with amoxicillin, a β-lactam antibiotic, under the name Augmentin. This restores susceptibility to β-lactam antibiotics to bacteria harbor β-Lactamase.\n\nThe other method to fight resistance is to create new antibiotics. We will aminoglycosides for this example. In the photo below, you see how aminoglycosides function: they use their positively charged amine groups (red) to ionically interact with the negatively charged phosphate backbone of ribosomal RNA (rRNA). Ribosomes are the machines of cells that synthesize proteins. By interacting with the phosphate backbone of rRNA, aminoglycosides inhibit protein synthesis, resulting in death.\n\n![](https://substackcdn.com/image/fetch/$s_!4wmi!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc209523-aef3-4509-b231-cc96777e271e_378x163.jpeg)\n\nOne mechanism bacteria have to resist aminoglycosides is through aminoglycoside modifying enzymes (AMEs), which deactivate the function of aminoglycosides by modifying their structure, similar to β-Lactamase with β-lactam antibiotics. One example is aminoglycoside-acetyltransferase (AAC) enzymes, which deactivate aminoglycosides by adding a chemical group known as an acetyl group to the positively charged amino groups (pictured below); this reaction neutralizes the positively charged amine groups, preventing the ionic interaction with the rRNA phosphate backbone.\n\n[![](https://substackcdn.com/image/fetch/$s_!d5Rv!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd4119e5f-0254-4143-a456-956832f3032e_1212x417.png)](https://substackcdn.com/image/fetch/$s_!d5Rv!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd4119e5f-0254-4143-a456-956832f3032e_1212x417.png)\n\nIn the photo below, you see the chemical structure of an antibiotic called amikacin. Amikacin is a semi-synthetic antibiotic, meaning it was derived from a naturally occurring antibiotic that was modified to create amikacin. Amikacin was developed by the Bristol-Banyu Research Institute and derived from kanamycin and had an L-hydroxyaminobuteroyl amide (L-HABA) group attached, indicated by the black box, creating amikacin. The L-HABA group makes amikacin impervious to modification by most AMEs because the L-HABA group makes it difficult for these enzymes to recognize and bind to amikacin to initiate the modification reaction. However, one enzyme remains notorious for being able to acetylate amikacin: Aminoglycoside-6’-N-Acetyltransferase subtype Ib (AAC(6’)-Ib). This enzyme acetylates amikacin at a position called the 6’ position, indicated in the red circle below. This enzyme was studied extensively in my graduate school lab.\n\n[![](https://substackcdn.com/image/fetch/$s_!i64v!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F55aa9148-b103-4bd2-add8-861d4fd0013f_652x377.png)](https://substackcdn.com/image/fetch/$s_!i64v!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F55aa9148-b103-4bd2-add8-861d4fd0013f_652x377.png)\n\nAmikacin’s commercial use began in 1976 and was offered as a better alternative to its source, kanamycin. The drug was extremely effective and Bristol-Banyu made tremendous profits.\n\nPlazomicin was created by Achaogen and is also semisynthetic and was derived from sisomicin. Like amikacin, plazomicin also had an L-HABA group added for similar reasons, indicated by the black box in the photo below to give it similar resistance to AMEs as amikacin. In addition, plazomicin also has an ethylhydroxyl group added to the 6’ amine group, indicated by the red circle. This modification makes plazomicin impervious to modification by AAC(6’)-Ib.\n\n[![](https://substackcdn.com/image/fetch/$s_!rZRE!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa0a9bb78-a4f2-48c8-8675-747637a8a5bb_520x331.png)](https://substackcdn.com/image/fetch/$s_!rZRE!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa0a9bb78-a4f2-48c8-8675-747637a8a5bb_520x331.png)\n\nPlazomicin received FDA approval in 2018. You would expect it to yield similar profits to amikacin, but instead, Achaogen went bankrupt. This is because the antibiotic market and use have changed significantly since Amikacin’s development. Today, new antibiotics are shelved as last resorts to contain the spread of antibiotic resistance. As a result, Achaogen could not find a robust market for plazomicin and had to declare bankruptcy after spending over $1 billion developing it. As a result, antibiotic development is all but dead; there is no profit in it, and by the time the antibiotic becomes needed for widespread use, the patent will have long expired, and anyone can make it, creating competition. This is a case where *Zero to One*’s thesis falls short. Not exactly something you want to hear when superbugs are projected to kill 10 million people annually in 2050.\n\nTo counter the shortcomings in the antibiotic market, Congress introduced the Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act in 2020. The bill has received bipartisan support. The bill establishes a subscription model for antibiotics, rewarding companies for developing, not selling antibiotics. This funding decouples revenue from sales and ensures a steady stream of revenue for companies developing antibiotics. Despite this, the bill has stalled in Congress for many reasons.\n\nOne reason is that the FDA typically approves antibiotics based on non-inferiority studies: simply showing the antibiotic isn’t worse than existing options. This makes the bill susceptible to “me-too” drugs or drugs that are structurally similar to existing antibiotics. It might encourage the development of other aminoglycosides without having inherent superiority over other aminoglycosides in subverting AMEs like amikacin and plazomicin. However, there is a key flaw with this criticism.\n\nIt’s difficult to assess superiority when a bacteria is susceptible to an existing antibiotic. If an infection can be cured with amikacin, plazomicin wouldn’t be superior. The real test is seeing if plazomicin can kill AAC(6’)-Ib-harboring bacteria in media and then seeing if animal models infected with said bacteria have a higher survival rate when treated with plazomicin instead of amikacin. The problem lies in the next step of approval: clinical trials. In clinical trials, you can’t intentionally infect a person with such superbugs and decide if they get amikacin, the “placebo,” or plazomicin. Intentionally infecting people is unethical and illegal; if the former wasn’t an issue for you, the latter will be. This is why superiority is hard to do in clinical studies but easy in translational studies (animal models) and superiority data should rely mostly on animal studies. Plazomicin was approved for complicated urinary tract infections (UTIs); the clinical data tested UTIs and bloodstream infections (BSI). It wasn’t approved for BSI treatment only because enrollment for the BSI study was too low to establish statistical significance, not because plazomicin was inferior to colistin, the “placebo.” Colistin is also a last-resort antibiotic, like plazomicin, but it is not an aminoglycoside antibiotic. The BSI animal model study compared plazomicin with tigecycline and showed that plazomicin was statistically superior, but tigecycline wasn’t an aminoglycoside either. The only time plazomicin was compared to other aminoglycosides was when it was used on carbapenem-resistant Enterobacterales (CRE) isolates in vitro (in laboratory equipment instead of animal models), where plazomicin showed vastly superior results to gentamicin, tobramycin, and amikacin. They should have included sisomicin since it was the base antibiotic for plazomicin, but I digress since I suspect the goal of plazomicin was to have similar properties to amikacin with the L-HABA group in addition to the ethylhydroxyl group was likely meant to make it impervious to AAC(6’)-Ib; comparing it to amikacin is sufficient for me given the history, chemistry, and biology.\n\nWhile I cannot say with absolute certainty, I can strongly infer plazomicin was designed with AAC(6’)-Ib in mind given the additional modification to the 6’ position. AAC enzymes are named based on the position they modify; if an enzyme is called AAC(6’), it means it acetylates at the 6’ position; if an enzyme is called AAC(2’), it acetylates at the 2’ position. Given AAC(6’)-Ib being an extremely prevalent enzyme and the only enzyme that can acetylate amikacin, the evidence strongly suggests plazomicin was designed to be impervious to AAC(6’)-Ib. Therefore, a true superiority study would be if plazomicin was superior to amikacin and non-inferior to other antibiotics, especially from other classes. The fact that plazomicin proves superior to amikacin in vitro establishes the superiority aspect and at least non-inferiority in translational and clinical studies shows plazomicin is an effective treatment not just for UTIs, but also BSIs. Therefore, the criteria for funding would be if they’re creating an antibiotic that is impervious to a prevalent mechanism of resistance and is superior to other antibiotics in its class that is susceptible to that resistance mechanism and if it’s non-inferior to existing last-resort antibiotics in different classes.\n\nA second reason the PASTEUR Act has been slow to pass is that people criticize the complexity of the bill. One concern is how they are supposed to decide which criteria to use to ensure truly innovative drugs are going to be invented. I already laid out one criterion: show that it is impervious to a prevalent resistance mechanism that subverts other antibiotics in its class. With AI, it becomes extremely easy to design an antibiotic that works based on previous attempts that worked. Let’s not forget other countries are already doing this, so we’re not starting from scratch. We can base the PASTEUR Act’s implementation based on those countries; invite experts from their country to come in and make suggestions. We must keep in mind that virtually nothing works as well in theory as it does in practice; they come with pros and cons and it comes down to balancing the two when designing our approach to the PASTEUR Act.\n\nA third reason is that Congress has its priorities shifted elsewhere. A bill must be reintroduced to each new Congress (in other words, every two years when a new Congress is elected) if it wasn’t voted on; the PASTEUR Act has been reintroduced to every Congress since its introduction, showing its importance.\n\nHowever, I saw a video from social media influencer Allie Voss who said US Congress requires controversy and I have to agree with that. Controversial news gets coverage, while bipartisan news doesn’t. A bipartisan bill should pass easily and wouldn’t even require the president’s signature since they can easily override a veto. But instead, this bill has been on the back burner for multiple Congresses now. It’s only when superbugs start killing people at an alarming rate that the PASTEUR Act gets any significant coverage. Our only other option is to unite and demand Congress passes the PASTEUR Act; this is the only way the PASTEUR Act passes proactively instead of reactively.\n\nThis article is an excerpt from a book I am writing about the economics of innovation and creating change.\n\nMy next article will be on how assessing market fit is different for healthcare.\n","body_html":"<p>In the fight against antibiotic resistance, there are two methods to fight it: the first is to inhibit their resistance mechanisms by mixing an inhibitor with the antibiotic and we will discuss β-lactam antibiotics with this example. In the picture below, you see a chemical structure commonly seen in β-lactam antibiotics. This structure is essential to their function. Β-lactam antibiotics work by inhibiting cell wall synthesis. To divide, bacteria must digest their cell wall, which protects them from lysing under osmotic pressure. Once they finish dividing, the bacteria must resynthesize their cell wall, or they risk rupturing. Β-lactams inhibit this synthesis, leaving the bacteria vulnerable to osmotic pressure, resulting in their eventual death.</p>\n<p><a href=\"https://substackcdn.com/image/fetch/$s_!HANd!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1b6bc2e4-e72c-4fa6-9691-d46145e362f9_250x287.png\" rel=\"nofollow ugc noopener\"><img src=\"https://substackcdn.com/image/fetch/$s_!HANd!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1b6bc2e4-e72c-4fa6-9691-d46145e362f9_250x287.png\" alt=\"\" loading=\"lazy\" decoding=\"async\" referrerpolicy=\"no-referrer\" /></a></p>\n<p>In the photo below, you see the mechanism of an enzyme called β-Lactamase, which hydrolyzes the β-lactam ring, deactivating the antibiotic.</p>\n<p><a href=\"https://substackcdn.com/image/fetch/$s_!N7bV!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd9979fc9-6a2a-4436-9c77-c92af5336939_777x268.png\" rel=\"nofollow ugc noopener\"><img src=\"https://substackcdn.com/image/fetch/$s_!N7bV!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd9979fc9-6a2a-4436-9c77-c92af5336939_777x268.png\" alt=\"\" loading=\"lazy\" decoding=\"async\" referrerpolicy=\"no-referrer\" /></a></p>\n<p>There is an inhibitor of β-Lactamase called clavulanic acid; it is sold as a cocktail with amoxicillin, a β-lactam antibiotic, under the name Augmentin. This restores susceptibility to β-lactam antibiotics to bacteria harbor β-Lactamase.</p>\n<p>The other method to fight resistance is to create new antibiotics. We will aminoglycosides for this example. In the photo below, you see how aminoglycosides function: they use their positively charged amine groups (red) to ionically interact with the negatively charged phosphate backbone of ribosomal RNA (rRNA). Ribosomes are the machines of cells that synthesize proteins. By interacting with the phosphate backbone of rRNA, aminoglycosides inhibit protein synthesis, resulting in death.</p>\n<figure><img src=\"https://substackcdn.com/image/fetch/$s_!4wmi!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc209523-aef3-4509-b231-cc96777e271e_378x163.jpeg\" alt=\"\" loading=\"lazy\" decoding=\"async\" referrerpolicy=\"no-referrer\" /></figure>\n<p>One mechanism bacteria have to resist aminoglycosides is through aminoglycoside modifying enzymes (AMEs), which deactivate the function of aminoglycosides by modifying their structure, similar to β-Lactamase with β-lactam antibiotics. One example is aminoglycoside-acetyltransferase (AAC) enzymes, which deactivate aminoglycosides by adding a chemical group known as an acetyl group to the positively charged amino groups (pictured below); this reaction neutralizes the positively charged amine groups, preventing the ionic interaction with the rRNA phosphate backbone.</p>\n<p><a href=\"https://substackcdn.com/image/fetch/$s_!d5Rv!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd4119e5f-0254-4143-a456-956832f3032e_1212x417.png\" rel=\"nofollow ugc noopener\"><img src=\"https://substackcdn.com/image/fetch/$s_!d5Rv!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd4119e5f-0254-4143-a456-956832f3032e_1212x417.png\" alt=\"\" loading=\"lazy\" decoding=\"async\" referrerpolicy=\"no-referrer\" /></a></p>\n<p>In the photo below, you see the chemical structure of an antibiotic called amikacin. Amikacin is a semi-synthetic antibiotic, meaning it was derived from a naturally occurring antibiotic that was modified to create amikacin. Amikacin was developed by the Bristol-Banyu Research Institute and derived from kanamycin and had an L-hydroxyaminobuteroyl amide (L-HABA) group attached, indicated by the black box, creating amikacin. The L-HABA group makes amikacin impervious to modification by most AMEs because the L-HABA group makes it difficult for these enzymes to recognize and bind to amikacin to initiate the modification reaction. However, one enzyme remains notorious for being able to acetylate amikacin: Aminoglycoside-6’-N-Acetyltransferase subtype Ib (AAC(6’)-Ib). This enzyme acetylates amikacin at a position called the 6’ position, indicated in the red circle below. This enzyme was studied extensively in my graduate school lab.</p>\n<p><a href=\"https://substackcdn.com/image/fetch/$s_!i64v!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F55aa9148-b103-4bd2-add8-861d4fd0013f_652x377.png\" rel=\"nofollow ugc noopener\"><img src=\"https://substackcdn.com/image/fetch/$s_!i64v!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F55aa9148-b103-4bd2-add8-861d4fd0013f_652x377.png\" alt=\"\" loading=\"lazy\" decoding=\"async\" referrerpolicy=\"no-referrer\" /></a></p>\n<p>Amikacin’s commercial use began in 1976 and was offered as a better alternative to its source, kanamycin. The drug was extremely effective and Bristol-Banyu made tremendous profits.</p>\n<p>Plazomicin was created by Achaogen and is also semisynthetic and was derived from sisomicin. Like amikacin, plazomicin also had an L-HABA group added for similar reasons, indicated by the black box in the photo below to give it similar resistance to AMEs as amikacin. In addition, plazomicin also has an ethylhydroxyl group added to the 6’ amine group, indicated by the red circle. This modification makes plazomicin impervious to modification by AAC(6’)-Ib.</p>\n<p><a href=\"https://substackcdn.com/image/fetch/$s_!rZRE!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa0a9bb78-a4f2-48c8-8675-747637a8a5bb_520x331.png\" rel=\"nofollow ugc noopener\"><img src=\"https://substackcdn.com/image/fetch/$s_!rZRE!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa0a9bb78-a4f2-48c8-8675-747637a8a5bb_520x331.png\" alt=\"\" loading=\"lazy\" decoding=\"async\" referrerpolicy=\"no-referrer\" /></a></p>\n<p>Plazomicin received FDA approval in 2018. You would expect it to yield similar profits to amikacin, but instead, Achaogen went bankrupt. This is because the antibiotic market and use have changed significantly since Amikacin’s development. Today, new antibiotics are shelved as last resorts to contain the spread of antibiotic resistance. As a result, Achaogen could not find a robust market for plazomicin and had to declare bankruptcy after spending over $1 billion developing it. As a result, antibiotic development is all but dead; there is no profit in it, and by the time the antibiotic becomes needed for widespread use, the patent will have long expired, and anyone can make it, creating competition. This is a case where <em>Zero to One</em>’s thesis falls short. Not exactly something you want to hear when superbugs are projected to kill 10 million people annually in 2050.</p>\n<p>To counter the shortcomings in the antibiotic market, Congress introduced the Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act in 2020. The bill has received bipartisan support. The bill establishes a subscription model for antibiotics, rewarding companies for developing, not selling antibiotics. This funding decouples revenue from sales and ensures a steady stream of revenue for companies developing antibiotics. Despite this, the bill has stalled in Congress for many reasons.</p>\n<p>One reason is that the FDA typically approves antibiotics based on non-inferiority studies: simply showing the antibiotic isn’t worse than existing options. This makes the bill susceptible to “me-too” drugs or drugs that are structurally similar to existing antibiotics. It might encourage the development of other aminoglycosides without having inherent superiority over other aminoglycosides in subverting AMEs like amikacin and plazomicin. However, there is a key flaw with this criticism.</p>\n<p>It’s difficult to assess superiority when a bacteria is susceptible to an existing antibiotic. If an infection can be cured with amikacin, plazomicin wouldn’t be superior. The real test is seeing if plazomicin can kill AAC(6’)-Ib-harboring bacteria in media and then seeing if animal models infected with said bacteria have a higher survival rate when treated with plazomicin instead of amikacin. The problem lies in the next step of approval: clinical trials. In clinical trials, you can’t intentionally infect a person with such superbugs and decide if they get amikacin, the “placebo,” or plazomicin. Intentionally infecting people is unethical and illegal; if the former wasn’t an issue for you, the latter will be. This is why superiority is hard to do in clinical studies but easy in translational studies (animal models) and superiority data should rely mostly on animal studies. Plazomicin was approved for complicated urinary tract infections (UTIs); the clinical data tested UTIs and bloodstream infections (BSI). It wasn’t approved for BSI treatment only because enrollment for the BSI study was too low to establish statistical significance, not because plazomicin was inferior to colistin, the “placebo.” Colistin is also a last-resort antibiotic, like plazomicin, but it is not an aminoglycoside antibiotic. The BSI animal model study compared plazomicin with tigecycline and showed that plazomicin was statistically superior, but tigecycline wasn’t an aminoglycoside either. The only time plazomicin was compared to other aminoglycosides was when it was used on carbapenem-resistant Enterobacterales (CRE) isolates in vitro (in laboratory equipment instead of animal models), where plazomicin showed vastly superior results to gentamicin, tobramycin, and amikacin. They should have included sisomicin since it was the base antibiotic for plazomicin, but I digress since I suspect the goal of plazomicin was to have similar properties to amikacin with the L-HABA group in addition to the ethylhydroxyl group was likely meant to make it impervious to AAC(6’)-Ib; comparing it to amikacin is sufficient for me given the history, chemistry, and biology.</p>\n<p>While I cannot say with absolute certainty, I can strongly infer plazomicin was designed with AAC(6’)-Ib in mind given the additional modification to the 6’ position. AAC enzymes are named based on the position they modify; if an enzyme is called AAC(6’), it means it acetylates at the 6’ position; if an enzyme is called AAC(2’), it acetylates at the 2’ position. Given AAC(6’)-Ib being an extremely prevalent enzyme and the only enzyme that can acetylate amikacin, the evidence strongly suggests plazomicin was designed to be impervious to AAC(6’)-Ib. Therefore, a true superiority study would be if plazomicin was superior to amikacin and non-inferior to other antibiotics, especially from other classes. The fact that plazomicin proves superior to amikacin in vitro establishes the superiority aspect and at least non-inferiority in translational and clinical studies shows plazomicin is an effective treatment not just for UTIs, but also BSIs. Therefore, the criteria for funding would be if they’re creating an antibiotic that is impervious to a prevalent mechanism of resistance and is superior to other antibiotics in its class that is susceptible to that resistance mechanism and if it’s non-inferior to existing last-resort antibiotics in different classes.</p>\n<p>A second reason the PASTEUR Act has been slow to pass is that people criticize the complexity of the bill. One concern is how they are supposed to decide which criteria to use to ensure truly innovative drugs are going to be invented. I already laid out one criterion: show that it is impervious to a prevalent resistance mechanism that subverts other antibiotics in its class. With AI, it becomes extremely easy to design an antibiotic that works based on previous attempts that worked. Let’s not forget other countries are already doing this, so we’re not starting from scratch. We can base the PASTEUR Act’s implementation based on those countries; invite experts from their country to come in and make suggestions. We must keep in mind that virtually nothing works as well in theory as it does in practice; they come with pros and cons and it comes down to balancing the two when designing our approach to the PASTEUR Act.</p>\n<p>A third reason is that Congress has its priorities shifted elsewhere. A bill must be reintroduced to each new Congress (in other words, every two years when a new Congress is elected) if it wasn’t voted on; the PASTEUR Act has been reintroduced to every Congress since its introduction, showing its importance.</p>\n<p>However, I saw a video from social media influencer Allie Voss who said US Congress requires controversy and I have to agree with that. Controversial news gets coverage, while bipartisan news doesn’t. A bipartisan bill should pass easily and wouldn’t even require the president’s signature since they can easily override a veto. But instead, this bill has been on the back burner for multiple Congresses now. It’s only when superbugs start killing people at an alarming rate that the PASTEUR Act gets any significant coverage. Our only other option is to unite and demand Congress passes the PASTEUR Act; this is the only way the PASTEUR Act passes proactively instead of reactively.</p>\n<p>This article is an excerpt from a book I am writing about the economics of innovation and creating change.</p>\n<p>My next article will be on how assessing market fit is different for healthcare.</p>","headings":[]}}